A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic... by Lev Demidov, Galina Kharkevich, Natalia Petenko, Vladimir Moiseenko, Svetlana Protsenko, Tatiana Semiglazova, Anastasia Zimina, Nadezhda Kovalenko, Natalia Fadeeva, Dmitry Kirtbaya, Igor Belogortsev, Denis Tantsyrev, Svetlana Odintsova, Alfia Nesterova, Karina Vorontsova, Yulia Makarycheva, Yulia Linkova, Arina Zinkina-Orikhan, Anna Siliutina, Irina Sorokina, Irina Sorokina, Daria Liaptseva, Vladimir Chistyakov, Anton Lutsky

Get full text